MONALEESA-2 demonstrates ribociclib plus letrozole overall survival benefit

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Sep 18 / Springer Healthcare

MONALEESA-2 demonstrates ribociclib plus letrozole overall survival benefit

Oncology Breast Cancer ESMO-2021

Description

Independent commentator Matteo Lambertinit discusses the finding of a significant overall survival benefit for ribociclib addition in patients with HR-positive, HER2-negative advanced breast cancer

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.